Company Profile
Kiora Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- KPRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.54 USD (-0.39%)
Close
Last updated: July 27, 2026
12.1M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, KPRX closed down 0.39% at $2.54. No new same-company headline was identified in the current news window.
Company overview
Business overview
Kiora Pharmaceuticals is a biotechnology company focused on ophthalmology and retinal disease. Its story is centered on developing treatments for eye diseases where local delivery and specialized biology matter.
Geographic Base and Sector Classification
Kiora is headquartered in the United States and listed on NASDAQ. It sits in ophthalmology biotechnology.
Business Model Characteristics
The company depends on clinical progress, ophthalmology-specific data, and the ability to fund a narrow pipeline. Investors typically watch proof-of-concept, safety, and platform strategy.
Position Within the Biotechnology Landscape
Kiora occupies a focused eye-disease niche within biotech. It is catalyst-sensitive because ophthalmology programs often depend on a small number of milestones.
Future catalysts
The main thing to watch at Kiora Pharmaceuticals is ABACUS-2, KIO-301, and the rest of its current pipeline. The update that sharpened the story was First Quarter 2026 and Recent Highlights Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodate the strong.... That is the part of the story investors will probably keep circling back to.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL · Source: Ocular Therapeutix
- 02
- 03
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
LENZ · Source: Lenz Therapeutics Inc
- 04
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Source: Kiora Pharmaceuticals
- 05
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
OCUL · Source: Ocular Therapeutix
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Kiora Pharmaceuticals (KPRX)?
Kiora Pharmaceuticals (KPRX) most recently closed at 2.54 USD, a -0.39% move versus the previous session.
What is the market cap of Kiora Pharmaceuticals (KPRX)?
Kiora Pharmaceuticals currently has a market capitalization of 12.1M USD on BioPharmSignal.
What does Kiora Pharmaceuticals do?
Kiora Pharmaceuticals is a biotechnology company focused on ophthalmology and retinal disease. Its story is centered on developing treatments for eye diseases where local delivery and specialized biology matter.
On which exchange is KPRX stock listed?
Kiora Pharmaceuticals (KPRX) is associated with NASDAQ, United States, Biopharma.
What is ABACUS-2?
The main thing to watch at Kiora Pharmaceuticals is ABACUS-2, KIO-301, and the rest of its current pipeline.
Which conditions is Kiora Pharmaceuticals targeting with ABACUS-2?
Kiora Pharmaceuticals is associated with ophthalmology based on its company overview and current catalyst commentary.
How does Kiora Pharmaceuticals describe recent progress with ABACUS-2?
The main thing to watch at Kiora Pharmaceuticals is ABACUS-2, KIO-301, and the rest of its current pipeline.
What is KIO-301?
The main thing to watch at Kiora Pharmaceuticals is ABACUS-2, KIO-301, and the rest of its current pipeline.